Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | SLC2A1 | P11166 | 1/20 | 1.00 |
| ▸ | GBA1 | P04062 | 2/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Anisomycin SCHEMBL18059879 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2CYP2D6ALDH1A1LMNAMAPK1 | |
| Anisomycin SCHEMBL8331774 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2CYP2D6ALDH1A1LMNAMAPK1 | |
| Anisomycin SCHEMBL2270183 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2CYP2D6ALDH1A1LMNAMAPK1 | |
| Anisomycin SCHEMBL59587 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2CYP2D6ALDH1A1LMNAMAPK1 | |
| Anisomycin SCHEMBL15033472 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2CYP2D6ALDH1A1LMNAMAPK1 | |
| Anisomycin SCHEMBL2270187 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2CYP2D6ALDH1A1LMNAMAPK1 | |
| Anisomycin SCHEMBL898674 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2CYP2D6ALDH1A1LMNAMAPK1 | |
| Anisomycin SCHEMBL1003579 | 0.99 | SMN1; SMN2 (0.97) | SMN1; SMN2CYP2D6ALDH1A1LMNAMAPK1 | |
| Anisomycin SCHEMBL6888777 | 0.94 | SMN1; SMN2 (0.89) | SMN1; SMN2CYP2D6ALDH1A1LMNAMAPK1 | |
| SCHEMBL18106096 | 0.88 | CYP2D6 (0.78) | SMN1; SMN2CYP2D6ALDH1A1LMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021007551-A1 | LONGEVITY SIGNATURES AND THEIR APPLICATIONS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2021-01-14 | — | — | WO | claimed |
| WO-2007002587-A2 | INHIBITORS OF EPSTEIN BARR VIRUS NUCLEAR ANTIGEN 1 | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2007-01-04 | — | — | WO | claimed |
| JP-63146818-A | — | — | None | — | — | JP | disclosed |
| EP-4397770-A1 | STABILISATION AND ISOLATION OF EXTRACELLULAR NUCLEIC ACIDS | PreAnalytiX GmbH (CH) | 2024-07-10 | — | — | EP | disclosed |
| EP-3401406-B1 | STABILISATION AND ISOLATION OF EXTRACELLULAR NUCLEIC ACIDS | PREANALYTIX GMBH (CH) | 2023-11-29 | — | — | EP | disclosed |
| EP-3226883-B1 | COMPOSITIONS FOR TREATMENT OF RETINAL DEGENERATIVE DISEASES | MOR RESEARCH APPLIC LTD (IL) | 2023-11-22 | — | — | EP | disclosed |
| US-20220249504-A1 | LONGEVITY SIGNATURES AND THEIR APPLICATIONS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2022-08-11 | — | — | US | disclosed |
| WO-2021007551-A1 | LONGEVITY SIGNATURES AND THEIR APPLICATIONS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2021-01-14 | — | — | WO | disclosed |
| EP-3447141-B1 | STABILISATION OF BIOLOGICAL SAMPLES | PREANALYTIX GMBH (CH) | 2020-08-05 | — | — | EP | disclosed |
| US-10682328-B2 | Compositions and methods for treatment of retinal degenerative diseases | MOR RESEARCH APPLICATIONS LTD. (IL) | 2020-06-16 | — | — | US | disclosed |
| US-20190350923-A1 | NATURAL COMPOUNDS AND FIBROSIS | MEDIZINISCHE HOCHSCHULE HANNOVER (MHH) (DE) | 2019-11-21 | — | — | US | disclosed |
| EP-0339709-B1 | ANTIFUNGAL COMPOSITIONS AND METHOD OF CONTROLLING MYCOTIC INFECTIONS | MERCK & CO. INC. (US) | 1993-03-31 | — | — | EP | disclosed |
| US-4921844-A | 25-AZASTEROLS, B-KETOTHIOLASE INHIBITORS | MERCK & CO., INC. (US) | 1990-05-01 | — | — | US | disclosed |
| US-4920111-A | SYNERGISTIC | MERCK & CO., INC. (US) | 1990-04-24 | — | — | US | disclosed |
| US-4920113-A | TO ERADICATE MYCOTIC INFECTIONS; NONTOXIC, SIDE EFFECT REDUCTION | MERCK & CO., INC. (US) | 1990-04-24 | — | — | US | disclosed |
| US-4920109-A | COADMINISTERING A 25-AZASTEROL WITH A NON-STEROIDAL AGENT; NONTOXIC, SIDE EFFECT REDUCTION | MERCK & CO., INC. (US) | 1990-04-24 | — | — | US | disclosed |
| US-4920112-A | SYNERGISTIC 25-AZASTEROL COMPOUND AND SQUALENE EPOXIDASE INHIBITOR | MERCK & CO., INC. (US) | 1990-04-24 | — | — | US | disclosed |
| EP-0339709-A2 | Antifungal compositions and method of controlling mycotic infections | MERCK & CO. INC. (US) | 1989-11-02 | — | — | EP | disclosed |
| EP-0339708-A2 | Fungicidal compositions and method | MERCK & CO. INC. (US) | 1989-11-02 | — | — | EP | disclosed |
| JP-S63146818-A | TREATING AGENT FOR VIRAL DISEASE | UENO SEIYAKU OYO KENKYUSHO:KK | 1988-06-18 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190350923-A1 | NATURAL COMPOUNDS AND FIBROSIS | MMP1, MKI67, HES1 | SMN1; SMN2 4402/4885CYP2D6 4703/4885ALDH1A1 221/4885 |
| US-10682328-B2 | Compositions and methods for treatment of retinal degenerative diseases | ALDH1A2, CLN6, NR2E3 | SMN1; SMN2 425/4885CYP2D6 4618/4885ALDH1A1 1288/4885 |
| US-20220249504-A1 | LONGEVITY SIGNATURES AND THEIR APPLICATIONS | GLA, LIMS1, GLB1 | SMN1; SMN2 217/4885CYP2D6 4614/4885ALDH1A1 2370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.